American Association of Individual Investors

Which Is a Better Investment, Catalyst Pharmaceuticals, Inc. or Zymeworks Inc. Stock?

Learn more about whether Catalyst Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
FierceBiotech

GSK cuts the cord on Ideaya collaboration, letting go of 2 programs

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...
pharmaphorum

GSK closes on approval of asthma hope depemokimab

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...
FiercePharma

GSK's long-acting asthma med scores in suite of CHMP drug endorsements

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...
FierceBiotech

Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. Paris-based Sanofi is investing in a U.S. biotech’s autoimmune research, while GSK ...
FiercePharma

GSK gains FDA expansion for Blujepa to treat gonorrhea

With an increase in the antimicrobial resistance to therapies for gonorrhea, doctors have been left with fewer options to treat the sexually transmitted infection (STI), which strikes more an 80 ...
Yahoo Finance

GSK Bolsters Oncology Pipeline with New US FDA Designation, Oxford BioTherapeutics Partnership

GSK (GSK.L) continues to strengthen its oncology portfolio, this time with a new regulatory designation for risvutatug rezetecan in the US and a cancer drug discovery collaboration with UK-based ...
Reuters

US FDA expands use of GSK's Blujepa as treatment for gonorrhea

Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has expanded the use of GSK's (GSK.L), opens new tab Blujepa as an oral treatment for gonorrhea, a common sexually ...
Reuters

European health regulator recommends approval for GSK's twice-yearly asthma drug

Dec 12 (Reuters) - The European Medicines Agency has recommended the approval of GSK's (GSK.L), opens new tab add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said ...
The Guardian

US is the best place for drug companies to invest, says boss of London-based GSK

Emma Walmsley’s praise for US pharmaceutical market piles pressure on UK government Business live – live updates The chief executive of GSK has declared that the US is the best place for ...
BBC

UK pharma boss says US is the best country to invest in

While successive governments have stressed that the UK is a superpower in life sciences, in the eyes of one of the country's biggest pharmaceutical companies, the US is the best place to invest. The ...